Adrenoleukodystrophy: Phenotypic variability and implications for therapy
- 1 July 1992
- journal article
- review article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 15 (4) , 645-664
- https://doi.org/10.1007/bf01799621
Abstract
X-linked adrenoleukodystrophy (ALD) is a relatively common disorder that shows a great deal of phenotypic variability. Approximately half of the patients have the rapidly progressive childhood cerebral form that is associated with an inflammatory response in brain and leads to total disability or death during the first decade. Twenty five per cent or more of the patients have adrenomyeloneuropathy (AMN), a form that progresses slowly, involves the spinal cord mainly, shows little or no inflammatory response, manifests in adulthood, and is compatible with a near-normal life span. The two forms of the disease occur frequently within the same kindreds and nuclear families. Segregation analysis based on 3862 individuals in 89 kindreds points to the existence of an autosomal modifier locus with a likelihood ratio of 20:1. In addition, we present preliminary results of three types of therapy. Two hundred and four patients have received a dietary regimen that combines the administration of oils containing mono-unsaturated fatty acids (oleic and erucic) with the restricted intake of very long-chain fatty acids. This regimen normalizes the levels of satured very long-chain fatty acids in plasma within 4 weeks. It appears to improve peripheral nerve function in patients with AMN, and a large-scale trial is in progress to determine whether it can prevent the onset of neurological involvement in patients who have the biochemical abnormality of ALD but are neurologically intact. We report early results of bone marrow transplantation in 14 patients. There is encouraging but still preliminary evidence that transplantation can arrest the progression of the disease in patients with mild neurological involvement. There is urgent need to develop methods to combat the rapid progression of the cerebral forms of the disease, which so far has resisted therapeutic intervention, including immunosuppression or the administration of immunoglobulin.Keywords
This publication has 45 references indexed in Scilit:
- Adrenoleukodystrophy: A correlation between saturated very long‐chain fatty acids in mononuclear cells and phenotypeAnnals of Neurology, 1991
- Clinical variation in X-linked adrenoleukodystrophy: Fatty acid and lipid metabolism in cultured fibroblastsBiochemical Medicine and Metabolic Biology, 1991
- Arachidonic acid metabolism in fibroblasts from patients with peroxisomal diseases: response to interleukin 1Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1990
- Reversal of Early Neurologic and Neuroradiologic Manifestations of X-Linked Adrenoleukodystrophy by Bone Marrow TransplantationNew England Journal of Medicine, 1990
- Adrenomyeloneuropathy Presenting as Addison's Disease in ChildhoodNew England Journal of Medicine, 1990
- Clinical improvement of adrenoleukodystrophy following intravenous gammaglobulin therapyBrain & Development, 1989
- Direct demonstration that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acidsBiochemical and Biophysical Research Communications, 1988
- Neuroepidemiology. Part II: Assessment of therapeutic trialsAnnals of Neurology, 1986
- Adrenoleukodystrophy: Evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous originBiochemical and Biophysical Research Communications, 1980
- Platelet dysfunction in the neonate with essential fatty acid deficiencyThe Journal of Pediatrics, 1977